Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases

被引：8
|
作者：
Tung, Nadine M.
Im, Seock-Ah
Senkus-Konefka, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Li, Wei
Armstrong, Anne Caroline
Conte, Pier Franco
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Robson, Mark E.
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Dana Farber Harvard Canc Ctr, Boston, MA USA
[3] Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea
[4] Med Univ Gdansk, Gdansk, Poland
[5] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[6] Peking Union Med Coll CAMS & PUMC, Beijing, Peoples R China
[7] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA
[8] Natl Hosp Org, Osaka, Japan
[9] Jilin Univ, Hosp 1, Changchun, Peoples R China
[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[11] Univ Padua, Padua, Italy
[12] Ist Oncol Veneto IRCCS, Padua, Italy
[13] AstraZeneca, Gaithersburg, MD USA
[14] AstraZeneca, Macclesfield, Cheshire, England
[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：2
相关论文
共 50 条
  • [41] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
    Tutt, Andrew Nicholas James
    Kaufman, Bella
    Gelber, Richard D.
    Mc Fadden, Eleanor
    Goessl, Carsten Dietrich
    Viale, Giuseppe
    Arahmani, Amal
    Fumagalli, Debora
    Azim, Hatem Abdel
    Wu, Wenting
    Grocholewicz, Anna
    Costantino, Joseph P.
    Rastogi, Priya
    Garber, Judy Ellen
    Geyer, Charles E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
    Tutt, A.
    Kaufman, B.
    Garber, J.
    Gelber, R.
    McFadden, E.
    Goessl, C.
    Viale, G.
    Geyer, C.
    Zardavas, D.
    Arahmani, A.
    Fumagalli, D.
    De Azambuja, E.
    Ponde, N.
    Herbolsheimer, P.
    Wu, W.
    Constantino, J.
    Rastogi, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients
    Endo, Yumi
    Dong, Yu
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Yamashita, Hiroko
    Sato, Shinya
    Takahashi, Satoru
    Fujii, Yoshitaka
    Toyama, Tatsuya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (07) : 619 - 623
  • [44] Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
    Lee, Kyung-Hun
    Sohn, Joohyuk
    Goodwin, Annabel
    Usari, Tiziana
    Lanzalone, Silvana
    Im, Seock-Ah
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 1084 - 1095
  • [45] S-1 versus taxanes for HER2-negative metastatic breast cancer
    Martin, Miguel
    Lopez-Tarruella, Sara
    LANCET ONCOLOGY, 2016, 17 (01): : 11 - 12
  • [46] EMBRACA: Efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: A regional analysis
    Mina, L.
    Lee, K-H
    Goncalves, A.
    Woodward, N.
    Hurvitz, S. A.
    Diab, S.
    Yerushalmi, R.
    Goodwin, A.
    Moreira Costa Zorzetto, M.
    Kim, S-B
    Czibere, A.
    Tudor, I. C.
    Gauthier, E.
    Litton, J. K.
    Ettl, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [47] Cost-effectiveness for companion BRCA testing and adjuvant olaparib treatment in patients with BRCA mutated high-risk HER2-negative early breast cancer
    Sheppard, E.
    Ma, W.
    Punekar, Y.
    Sagoo, G.
    Nikolova, S.
    VIRCHOWS ARCHIV, 2024, 485 : S347 - S347
  • [48] EFFICACY AND SAFETY OF ERIBULIN IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER: REAL LIFE EXPERIENCE
    Zhilyaeva, Larisa
    BREAST, 2017, 36 : S53 - S54
  • [49] Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)
    Tung, Nadine
    Arun, Banu
    Hofstatter, Erin
    Hacker, Michele R.
    Toppmeyer, Deborah L.
    Isakoff, Steven J.
    Borges, Virginia
    Legare, Robert D.
    Isaacs, Claudine
    Wolff, Antonio C.
    Marcom, Paul K.
    Mayer, Erica L.
    Lange, Paulina B.
    Goss, Andrew J.
    Krop, Ian E.
    Winer, Eric P.
    Schnitt, Stuart J.
    Garber, Judy E.
    CANCER RESEARCH, 2020, 80 (04)
  • [50] Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial
    Ettl, Johannes
    Hurvitz, Sara A.
    Rugo, Hope S.
    Lee, Kyung-Hun
    Mina, Lida A.
    Woodward, Natasha E.
    Yerushalmi, Rinat
    Diab, Sami
    Martin, Miguel
    Tudor, Iulia Cristina
    Czibere, Akos Gabor
    Gauthier, Eric Roland
    Litton, Jennifer Keating
    Goncalves, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345